Special Investigation Of J Zoloft For Panic Disorder Patients
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The objective of this surveillance is to collect information for panic disorder patients
about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions),
2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to
affect the safety and/or efficacy of this drug.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.